Amendments No. 2 and No. 3 to the 2020 GSK collaboration agreement, removing the CoV Vaccine Program and modifying the coronavirus antibody program, with tiered royalties payable to GSK.
| Officer | Age | 2025 pay | Source |
|---|---|---|---|
|
Marianne De Backer
Also a director
President and CEO
Title from the Form 4 dated Apr 29, 2026
|
57 | $7,834,045 | |
|
Aziz Sawaf
EVP, Chief Financial Officer
Title from the Form 4 dated Nov 15, 2026
|
Not stated | Not reported | |
|
Mark Eisner
Executive Vice President and Chief Medical Officer
|
60 | $2,371,484 | |
|
Vanina de Verneuil
EVP, General Counsel, Corp Sec
Title from the Form 4 dated Nov 2, 2026
|
47 | $1,690,784 | |
|
Brent Sabatini
SVP, Chief Accounting Officer
Title from the Form 4 dated Nov 15, 2026
|
Not stated | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 16, 2026 · updated by the 8-Ks of May 28, 2026, Jun 10, 2026, and Oct 28, 2026
| Director | Age | On board | Independent | Committees | Other public boards | 2025 pay | Source |
|---|---|---|---|---|---|---|---|
|
Jeffrey S. Hatfield
Board chair
|
68 |
2020
6 years
|
Independent |
Audit
Nominating and Corporate Governance · Chair
|
None stated | $184,645 | |
|
Marianne De Backer
CEO
|
57 |
2023
3 years
|
Not stated | None stated | None stated | Paid as CEO | |
|
Norbert Bischofberger
|
70 |
2024
2 years
|
Independent |
Compensation
Science and Technology
|
None stated | Not stated | |
|
Ramy Farid
|
61 |
2024
2 years
|
Independent |
Audit
Science and Technology
|
Schrödinger, Inc. | Not stated | |
|
Robert More
|
58 |
2016
10 years
|
Independent |
Audit · Chair
Compensation · Chair
|
Tyra Biosciences, Inc. (Chairman) (2021 – present) | $182,860 | |
|
Janet Napolitano
|
68 |
2020
6 years
|
Independent |
Compensation
Nominating and Corporate Governance
|
Fortinet, Inc. (2024 – present) | $159,975 | |
|
Elliott Sigal
|
74 |
2020
6 years
|
Independent |
Compensation
Science and Technology · Chair
|
Alnylam Pharmaceuticals, Inc. (2022 – present) | Not stated | |
|
Timothy Coughlin
Joined Jun 10, 2026
|
- | - | - |
Audit Committee · Chair
|
- | - | |
|
Suzanne Topalian
Joined Oct 27, 2026
|
- | - | - |
Science and Technology Committee
|
- | - | |
|
Vicki Sato
Leaving at the meeting
Board chair
|
Not stated | Not stated | Not stated | None stated | None stated | Not stated |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
Amendments No. 2 and No. 3 to the 2020 GSK collaboration agreement, removing the CoV Vaccine Program and modifying the coronavirus antibody program, with tiered royalties payable to GSK.
Letter Agreement terminating the collaboration on the Influenza Program under the Definitive Collaboration Agreement, with royalty payments to GW on certain influenza products.
Loading...